Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065182 · ClinicalTrials.gov registry record · Phase 2
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 399
- Enrollment target
NCT00065182 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 399 participants.
The verdict
NCT00065182, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 399 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.
Interventions
- DRUG Docetaxel
- DRUG Topotecan/Docetaxel combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2003-08-14 |
| Est. Completion | 2007-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065182
The ClinicalTrials.gov registry entry for NCT00065182 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 399 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00065182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065182 about?
NCT00065182 is a clinical study titled "Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer". The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.
What is the current status of trial NCT00065182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 399 participants. The study started on 2003-08-14. Estimated completion is 2007-08-30.
What interventions are being tested in trial NCT00065182?
The interventions under investigation include: Docetaxel (DRUG), Topotecan/Docetaxel combination (DRUG).
Who is sponsoring clinical trial NCT00065182?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.